This inventor holds 1 USPTO granted patent. Top assignee: Orion Corporation. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: Gerd Wohlfahrt and CYP11A1 Inhibitor Research.
Introduction
Gerd Wohlfahrt is an inventor associated with Munich, Germany, and Orion Corporation. His listed patent work concerns compounds investigated as CYP11A1 inhibitors, with potential applications in treating hormone-dependent diseases.
Latest Patents
The supplied information lists 1 patent for Wohlfahrt: “(2,3-dihydro-4H-benzo[b][1,4]oxazin-4-yl)(5-(phenyl)-pyridin-3-yl)methanone derivatives and similar compounds as CYP11A1 inhibitors for the treatment of prostate cancer.”
The patent describes compounds of formula (I), with specified variations in their chemical groups and linkers. These compounds are presented as inhibitors of cytochrome P450 monooxygenase 11A1 (CYP11A1). The disclosed potential uses include treating diseases dependent on steroid receptors, such as androgen-receptor-dependent prostate cancer and estrogen-receptor-dependent cancers.
Career Highlights
The provided information associates Wohlfahrt’s patent activity with Orion Corporation, a pharmaceutical company. The patent’s focus is on medicinal chemistry and the development of compounds intended to inhibit CYP11A1.
Collaborations
The listed coworkers are David Din Belle and Pekka Pietikäinen. The supplied details do not specify their individual roles in the patent or their broader professional relationship with Wohlfahrt.
Conclusion
Gerd Wohlfahrt’s listed invention centers on CYP11A1-inhibiting compounds and their potential use in treating steroid-receptor-dependent diseases, including prostate cancer.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile